FDA Approves NovoCure Device for mNSCLC Treatment

NovoCure ( (NVCR) ) has shared an update.

The FDA has approved Novocure’s Optune Lua for use with PD-1/PD-L1 inhibitors or docetaxel in treating metastatic non-small cell lung cancer (mNSCLC) patients who have progressed after platinum-based therapy. This wearable device, employing Tumor Treating Fields (TTFields), marks a significant breakthrough by improving median overall survival in this patient group, providing a promising new option free of severe systemic toxicity.

For an in-depth examination of NVCR stock, go to TipRanks’ Stock Analysis page.